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CASE PRESENTATION
A 14-year-old boy was referred to the Department of
Pediatric Nephrology at Hacettepe University Faculty of
Medicine because of nephrotic syndrome unresponsive
to a 1-month course of oral prednisone. He described
attacks of fever and joint complaints since the age of 7 that
occasionally were accompanied by chest or abdominal
pain. The attacks usually occurred over 1 to 3 days. These
joint complaints were either in the form of frank arthritis
in the ankle or knee joints, or arthralgia in the same joints.
He had been diagnosed as having acute rheumatic fever
by the local physician. However, his complaints recurred
despite penicillin prophylaxis.
One year ago he was diagnosed as having Henoch-
Scho¨nlein purpura because of severe vasculitic rash in the
lower exteremities and abdominal pain. He was admitted
to the district hospital at that time. His initial urinalysis
was said to be normal; however, there was no follow-up
after he was discharged. He had no family history of renal
disease. The parents were second-degree cousins.
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On admission he had a normal blood pressure, marked
edema, and a pale, waxy appearance. He had a normal
complete blood count and normal serum creatinine, and
a serum albumin of 2.1 g/dL. A 24-hour urine collec-
tion revealed 8.3 g of protein. His creatinine clearance
was 76 mL/min. Serum cholesterol and triglyceride levels
were mildly elevated. The acute-phase reactants were ele-
vated, with an erythrocyte sedimentation rate (ESR) of 98
mm/hour, C-reactive protein of 12 mg/dL (normal < 0.5),
and serum fibrinogen of 587 mg/dL. Serum complement
levels were normal. The antinuclear antibody (ANA),
anti-ds-DNA, and antineutrophil cytoplasmic antibody
(ANCA) all were negative.
A renal biopsy was performed. Light microscopy
showed eosinophlic, amorphous deposits in the mesan-
gial area of the glomeruli. Also visible were the char-
acteristic apple-green birefringence with polarized light
and orange-red staining with Congo red, suggesting renal
amyloidosis.
Evaluation for mutations in the MEFV (Mediter-
ranean fever) gene showed that the patient was homozy-
gous for the M694V mutation. He was given colchicine,
2 mg/day.
Although his attacks resolved with treatment, he
had persistent nephrotic syndrome, and his acute-phase
reactants remained high. His renal function started
deteriorating in a year. One year later, his serum cre-
atinine was 3.8 mg/dL. He started complaining of di-
arrhea and had difficulty in taking colchicine at the
suggested dose. He started dialysis 18 months after his
diagnosis. He continued to have approximately 600 mL
of urine output/daily with heavy proteinuria. His blood
pressure always was normal and even low, which re-
sulted in occasional problems with his arteriovenous fis-
tula. His serum albumin also remained low, around 2.5 g/
dL; his persistent and marked diarrhea exacerbated his
malnutrition.
Two years after diagnosis, he presented with fatigue,
dyspnea, and cough. He had severe pericardial and
pleural effusion and acute pneumonia. He was given
intensive antibiotic treatment, and discharged to con-
tinue hemodialysis in a local center. Three months
later, he was reported to have died with intractable
diarrhea.
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DISCUSSION
Dr. Seza Ozen (Professor, Department of Pediatrics,
Hacettepe University, Ankara, Turkey): This patient il-
lustrates a classic example of a misdiagnosis that led to
the complication of renal amyloidosis secondary to famil-
ial Mediterranean fever (FMF). Familial Mediterranean
fever is characterized by recurrent inflammatory attacks
[1–5]; its most severe complication is the development of
secondary amyloidosis of the kidney. This kidney disease
represents the only nephropathy that can be prevented
by a very inexpensive drug. Familial Mediterranean fever
is the commonest of the autoinflammatory diseases, or
the so-called periodic fever syndromes, that have re-
cently gained widespread interest [3, 6–8]. Some of these
diseases, like FMF, are characterized by an autosomal-
recessive inheritance, whereas others have a dominant
transmission. When the FMF gene was identified in 1997,
it was thought that the diagnosis would be made in the lab-
oratory [1, 9]. However, subsequent study has confirmed
that the diagnosis needs to be based on clinical criteria.
Classically, FMF is characterized by self-limited attacks
of fever and serositis presenting in the form of abdomi-
nal, joint, or chest pain along with an elevation of acute-
phase reactants. Although a number of diagnostic criteria
have been suggested [10], these criteria need validation
in various ethnic and multiethnic groups [10]. At present,
the diagnosis of FMF relies on careful follow-up, family
history exclusion of other periodic fever syndromes and
immune disorders and, finally, the patient’s response to
colchicine therapy.
The patient presented here had had attacks of fever and
self-limited arthritis that occasionally were accompanied
by abdominal pain. Episodes of arthritis/arthralgia are a
frequent feature of FMF and have been associated with
more severe disease in a number of reports [4, 11, 12].
The joints most frequently involved in FMF are the knees
and ankles. These patients are sometimes misdiagnosed
as having acute rheumatic fever, but their symptoms do
not respond to penicillin prophylaxis and these people
later present with amyloidosis. When questioned, today’s
patient also described serositis in the form of abdominal
and chest pain. However, these complaints had been ig-
nored by the physicians. The attacks were of a duration
typical among periodic fever syndromes.
This boy presented with nephrotic syndrome with-
out any nephritic features. Secondary amyloidosis of
FMF can present in a variety of successive forms that
reflect the severity of renal involvement [2, 13]: iso-
lated proteinuria, nephrotic syndrome, and renal im-
pairment with nephrotic features. The patient who
presents with nephrotic syndrome usually is normoten-
sive, and hematuria is very rare. Often, marked edema
and a waxy appearance of the skin are present. These
patients are often treated with steroids because of
an initial erroneous diagnosis of minimal change dis-
Fig. 1. Light microscopy of renal amyloidosis showing amorphous
deposits.
Fig. 2. Characteristic Congo red staining of amyloid deposits.
ease [14]. The patient, of course, had no response to
corticosteroids.
Diagnosis of amyloidosis is made through renal biopsy.
The characteristic finding comprises eosinophilic amor-
phous deposits in the mesangial matrix of the glomeruli
with hematoxylin-eosin staining (Fig. 1). Tissues stained
with Congo red have orange-red staining (Fig. 2). Under
polarized light, one sees a characteristic apple-green bire-
fringence diagnostic for amyloid deposition. The nature
of the amyloid fibrils can be confirmed by immunoper-
oxidase staining with specific monoclonal antibodies. In
FMF the fibrils are of the AA type, secondary to ongoing
inflammation. Bone marrow biopsy also is an alterna-
tive method for diagnosis. In patients with amyloidosis
secondary to FMF, 80% of the marrow biopsies showed
amyloidosis [13].
Although FMF is not the only periodic fever disease
causing secondary AA amyloidosis, it is the only one re-
sponsive to colchicine. One can make a fairly conclusive
1120 Nephrology Forum: Renal amyloidosis in FMF
diagnosis of FMF if the patient has at least three attacks of
fever plus abdominal and/or chest and/or joint pain; and
either (1) a diagnosis of FMF or amyloidosis has been
determined in a family member or is known to have been
present in an ancestor, or (2) infection is excluded as a
cause and the duration of the fever is 6 hours to 6 days.
The typical duration is 12 hours to 3 days. Also, FMF can
be diagnosed only in the absence of lymphadenopathy,
aphthous lesions, and rash (except erysipelas-like ery-
thema) and in the presence of elevated acute-phase reac-
tants. In patients with these criteria, the diagnosis of FMF
can be confirmed by a mutation analysis of the Mediter-
ranean fever (MEFV) gene. However, most centers in ar-
eas where the disease is common rely on clinical grounds
only. In this patient, subsequent mutation analysis of the
MEFV gene for FMF confirmed that he had a severe mu-
tation in both alleles, the M694V mutation.
Let’s talk for a moment about the pathogenesis of FMF.
The gene responsible for FMF was described only in 1997
[1, 9]. Although FMF is an ancient disease, the definition
of the gene and its protein has led to new interest in this
disease. The commonest of the group of monogenic au-
toinflammatory diseases, in which increased acute-phase
reactants are a feature of the disease per se, FMF has re-
cently emerged as an important topic [3, 6]. Understand-
ing these diseases promises to provide crucial information
about the pathway of inflammation in other diseases as
well.
The MEFV gene consists of 10 exons. Almost 30 mu-
tations of this gene have been associated with FMF so far
[4, 15, 16]. Mutations in the hot spot of exon 10, the region
between 680 and 694, seem to be associated with more se-
vere disease, whereas patients with the E148Q mutation
can be free of symptoms. Among the patients presenting
to our department, M694V is the most frequent muta-
tion, whereas the most frequent mutation among healthy
Turkish carriers is E148Q [17].
Expressed mainly in neutrophils and monocytes,
MEFV encodes a protein called pyrin (from the Latin
word for fever) [1]. Interestingly, most of the autoin-
flammatory diseases that I will mention also have this
pyrin domain in the affected protein [6]. Pyrin is an im-
portant element in the body’s inflammatory response.
Familial Mediterranean fever is a disorder of the innate
immune system, that is, the system responsible for quick
response to a variety of organisms [8]. A mutated pyrin
is associated with uncontrolled inflammation through in-
terleukin b (IL-b) and nuclear factor-kappaB (NF-jB)
activation and leads to up-regulation of inflammatory
cytokines and pathways. Pyrin interacts with apoptosis-
associated speck-like protein (ASC), which contains a
caspase recruitment domain that stimulates caspase-1 ac-
tivation. Caspase-1 activation then leads to IL-1 process-
ing and secretion and raises levels of IL-b [6, 8]. The
interaction with ASC also causes NF-jB activation, the
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Fig. 3. Suggested pathogenesis of familial Mediterranean fever (FMF).
Abbrevations are: IL-1b , interleukin-1b ; NF-jB, nuclear factor-
kappaB.
phosphorylation of which is associated with increased
transcriptional activity of certain inflammatory cytokines
(Fig. 3). Apoptosis is also induced through this pathway.
However, we are still not sure whether FMF is a proapop-
totic or antiapoptotic disease [8].
A mutated pyrin is probably associated with loss of
the delicate control of the inflammatory pathways. The
inflammatory state of FMF is associated with a Th1 pre-
dominance in the inflammatory reponse of the disease, as
in Behc¸et’s syndrome and rheumatoid arthritis. This Th1
polarization was suggested by studies from our lab, which
showed increased staining of interferon c (INF-c) in the
peripheral blood samples of patients with FMF [18].
The clinical disease, that is, the phenotype of FMF, is
very frequent around the Mediterranean, as is the carrier
rate in certain ethnic populations, namely, Arabs, Arme-
nians, non-Ashkenazi Jews, and Turks. The frequency of
affected individuals ranges between 1/250 and 1/1000 in
these populations [19–22]. Definition of the mutations
has led to interesting epidemiologic studies showing that
the disease and its carrier frequency are common. In the
affected populations, the carrier rate is extremely high:
1 in 3 to 1 in every 6 individuals carries a mutation in
the MEFV gene [17, 20, 23]. In fact, the reasons for the
frequent selection of such mutations in this gene are cur-
rently being debated [24].
Mutation analysis and haplotype associations have
helped us trace the ancestry of this disease at least 2500
years, when today’s affected populations were living to-
gether in the eastern Mediterranean basin [1]. After the
spread of MEFV mutations from the eastern Mediter-
ranean in biblical times, many migrations, including those
of the 20th century, have resulted in a larger distribu-
tion of the disease. Thus the disease is no longer con-
fined to eastern Mediterranean countries. Genetic studies
have shown that the disease is present in other European
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populations, albeit associated with milder mutations. In-
deed, one of the most frequent mutations in the patients
of European origin is E148Q, which is thought to be as-
sociated with a milder disease and even nonpenetrance
[15].
An increasing number of cases has been reported
among Askhenazi Jews and people of Italian ancestry
as well [20, 25]. Most of these patients have mild dis-
ease and less-characteristic features, as they carry mild
mutations. Familial Mediterranean fever has even been
described in Japanese patients [26]. Furthermore, the car-
rier rate for a mild mutation in the MEFV gene (E148Q)
was detected in 21 of 102 Indians in a study from England
[27]. Although the mutations are no longer confined to
the original groups, the FMF genetic alteration remains
highly selected in eastern Mediterranean populations.
What are the clinical findings in FMF? The mean age
of onset and age of diagnosis of FMF in a large Turkish
childhood series were 5.5 ± 3.4 years and 9.3 ± 3.7 years,
respectively [5]. In a multicenter study representing the
largest series of FMF, the mean ages of onset and diagno-
sis were 9.6 ± 8.6 years and 16.4 ± 11.6 years, respectively
(unpublished findings of a national multicenter study in
Turkey).
The signs and symptoms of FMF might or might not be
related to the attacks. Attack-related findings include [2,
5, 11, 16, 19, 28–30]: fever (in >90%), abdominal pain (in
>90%), arthritis or arthralgia (around 50%), chest pain
due to pleuritis (in approximately 33% of patients, but
much higher in Armenians) or pericarditis, erysipelas-
like erythema (varies, up to 20%), myalgia (varies, up to
33%), and scrotal attacks (fewer than 5%). The patient
can present with only one of these features during an at-
tack or with a combination of them. Typical attacks last
1 to 3 days. Some features are associated with a longer
duration, such as protracted febrile myalgia or, rarely,
protracted arthritis that can last for weeks. Signs and
symptoms not related to attacks also can occur. Exer-
tional myalgia of the calves and feet is common. Unilat-
eral and bilateral sacroiliitis also can be a feature of the
disease.
Renal involvement occurs in a number of forms. First,
nonamyloid glomerulopathies have been reported [31–
33]. In a nationwide study enrolling 2838 FMF patients
from Turkey, 22 had nonamyloid glomerular diseases
and displayed various types of glomerulopathies. Second,
peristent microscopic hematuria can occur during attacks
[2, 30]. Third, several reports have highlighted the fre-
quent association of FMF with certain vasculitides, espe-
cially Henoch-Scho¨nlein purpura (HSP) and polyarteritis
nodosa (PAN) [2, 34, 35]. These patients may well present
with renal vasculitis. Patients with FMF who develop
PAN have a younger age at onset as compared with pa-
tients without FMF, and the former seem to have some
peculiar features such as overlapping features of classic
PAN and microscopic polyangiitis as well as overall bet-
ter prognosis compared to patients without FMF. We had
hypothesized that the increase rate of these vasculitides
might be due to the heightened inflammatory response
in patients with FMF or that vasculitis might be an inte-
gral feature of FMF per se [34]. It is interesting that the
presented patient had been diagnosed as having HSP 1
year prior to presentation at our department. Renal in-
volvement of HSP might have been considered in the dif-
ferential diagnosis of this patient, but neither the clinical
course nor the biopsy was compatible with HSP nephri-
tis. Finally, if FMF is not treated, amyloid deposition can
ensue in several organs.
Renal amyloidosis in FMF and other auto-
inflammatory syndromes is secondary to the deposition
of amyloid A protein in the kidney [5, 30]. The precursor
of the deposited amyloid A protein is serum amyloid A
(SAA), an acute-phase reactant. Serum amyloid A is
produced by inflammatory signals, especially IL-1. Poly-
merization of SAA into amyloid fibrils requires removal
of the C terminal of the AA protein [4]. Amyloid fibrils
accumulate in extracellular spaces. The pathologic effect
of the deposited AA fibrils occurs because their physical
presence disrupts the structures in the kidney.
Many diseases associated with severe inflammation
have been associated with amyloidosis of the AA type;
among these are rheumatic diseases, such as rheuma-
toid arthritis, and infectious diseases, such as tuberculo-
sis. Both examples represent chronic diseases in which
inflammation persists for a prolonged period. In fact,
the persistent augmentation of an inflammatory pathway
through the innate immune system might be crucial in the
deposition of the amyloid protein.
Newly defined autoinflammatory diseases have been
associated with a significant risk of amyloidosis. Among
these, the tumor necrosis factor (TNF) receptor–
associated periodic fever syndrome (TRAPS), the most
common periodic fever disease after FMF, is associated
with high levels of circulating TNF [36]. Basically, the ge-
netic defect in the TNF receptor superfamily 1A results
in lower shedding, and thus lower levels, of the recep-
tor. The decreased amount of receptor available to bind
raises the levels of unbound TNF-a. The two other auto-
inflammatory syndromes associated with secondary amy-
loidosis, Muckle-Wells syndrome and chronic infantile
neurologic cutaneous articular syndrome, have a pyrin
domain that up-regulates IL-1b production [37–39]. Both
IL-1b and TNF markedly induce the hepatic synthesis of
two major acute-phase proteins, C-reactive protein, and
SAA. The level of SAA seems to correlate with the de-
velopment of amyloidosis [40]. Furthermore, the role of
high SAA levels has been further supported by the associ-
ation of amyloidosis with a certain SAA1 polymorphism
that leads to increased SAA levels in the three ethnic
populations studied [41–43].
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However, why FMF is so frequently associated with
renal amyloidosis remains to be clarified. Is it simply be-
cause there are increased amounts of acute-phase reac-
tants and especially SAA in the system? Some patients
do present with amyloidosis without any prior features
of FMF, the so-called “phenotype 2” patients [2, 5, 30].
The lack of clinical symptoms calls into question the pres-
ence of acute-phase reactant elevation in these patients.
However, we do not know whether these patients had
laboratory indices of intense inflammation but somehow
lacked clinical manifestations. One wonders whether an-
other genetic factor was involved in these patients.
Perhaps a defective pyrin is causing a lack of suppres-
sion of the deposition of amyloid fibrils. On the other
hand, since there is an increased risk of amyloidosis in
families with a history of amyloidosis, there seems to be
a separate genetic factor, or factors that might be segre-
gating within the family, and these factors might or might
not be linked to the MEFV gene locus.
In the precolchicine era, as many as 75% of adults with
FMF were reported as having amyloidosis [2, 44]. How-
ever, one must remember that these figures represented
the percentage among symptomatic patients in the late
1960s. In a recent multicenter Turkish survey enrolling
2838 patients, approximately 13% of the FMF patients
had amyloidosis. The risk for amyloidosis is much lower
among Arab patients with FMF. Thus not all patients with
FMF develop amyloidosis.
Many studies have tried to delineate the factors related
to the development of amyloidosis. The first suggested as
risk factors male gender [41] and the presence of sec-
ondary amyloidosis in the family [5]. We had suggested
in a small study that one or more modifying hereditary
factors might be involved in the segregation of amyloido-
sis within families [5]. Increased risk to individuals with
a family history of amyloidosis was confirmed in larger
studies. Many studies have indicted the M694V mutation
in association with amyloidosis [4, 11, 12, 15]. However,
amyloidosis is not confined to patients with this mutation,
and one group in Turkey reported a lack of association
of amyloidosis with the M694V mutation [45]. A number
of polymorphisms introduce an increased risk of amyloi-
dosis in FMF patients. The first of these is the SAA1 a/a
genotype, which introduces a risk of up to sevenfold in
patients with FMF [41]. This risk was confirmed in the
Armenian, Jewish, and Turkish populations [41–43]. An
Ala138Gly alteration in the MEFV gene also has been
suggested as a risk factor [46]. However, patients lacking
this polymorphism also can develop amyloidosis. Further,
studying these polymorphisms is not very easy on practi-
cal grounds. In the Turkish study, patients who developed
amyloidosis were younger at onset, and the delay in di-
agnosis was significantly longer (P = 0.001; unpublished
findings of a nationwide multicenter study in Turkey).
However, 5 of the 18 patients who experienced their first
attack after the age of 40 developed amyloidosis. Thus
the lack of symptoms during childhood does not protect
one from amyloidosis. The problem is even more com-
plicated in phenotype 2 patients. Environmental factors
also probably play a role, as Armenian patients with FMF
who live in the United States do not develop amyloidosis
[47].
Our patient had high acute-phase reactants, at least
when he was diagnosed, was homozygous for the M694V
mutation, and was male. He already had nephrotic syn-
drome due to renal amyloidosis when he presented to our
clinic. At the time we were unable to study the SAA levels
or polymorphisms. Clinically, renal amyloidosis generally
presents in one of three forms: proteinuric, nephrotic, and
renal failure.
Colchicine has been the drug of choice for patients
with FMF since the early 1980s. Instituted at a suffi-
cient dose when the patient is diagnosed, colchicine may
halt progression of the disease [5, 48]. Furthermore, re-
ports show that proteinuria can remit and even disap-
pear, although the renal amyloid deposition persists [2,
45, 49]. Colchicine treatment also is necessary for protec-
tion against amyloid deposition in other organs. In fact,
now that patients with renal amyloidosis live longer be-
cause of renal replacement therapy, the previously clin-
ically latent involvement of other organs, including the
gastrointestinal tract, heart, lungs, thyroid, and adrenal,
is becoming evident [2]. In today’s patient, gastrointesti-
nal amyloidosis was an important cause of morbidity and
mortality. Although we were not able to biopsy his lung,
we can speculate that his persistent lung complications
were related to amyloid deposition in the lung as well. I
do not know whether amyloid deposition in other organs
is more resistant to colchicine. Nor is it known whether
colchicine is absorbed adequately from the gastrointesti-
nal tract in patients with renal impairment; perhaps renal
dysfunction renders them more susceptible to amyloid
deposition in other organs as well.
The differential diagnosis of FMF involves a newly rec-
ognized group of diseases associated with autoinflamma-
tion [6]. These monogenic diseases all affect the IL-1
or TNF pathways, and most of them are associated
with a substantial risk of amyloidosis [6]. These diseases
were probably under-recognized until recently. The most
important feature differentiating FMF from the other
diseases is that only FMF responds to colchicine admin-
istration. All except FMF seem to be more frequent—
at least so far—in people of northwest European
ancestry. These diseases, all of which are associated with
short episodes of fever and some joint involvement, com-
prise six syndromes. The first of these, TRAPS [6, 36],
is autosomal-dominant, and its typical duration is > 1
week. TRAPS is associated with mutations in the TNF-
receptor superfamily 1. Rash is characteristic, with a mi-
gratory skin rash that usually comprises erythematous
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macules. Amyloidosis is common, and there is an asso-
ciation with cysteine mutations. The differentiating fea-
tures of TRAPS include myalgia (present in 80% of
patients), conjunctivitis and periorbital edema, and the
prolonged duration of attacks. Second, the hyper IgD
syndrome is autosomal-recessive [50, 51]. It typically lasts
for 3 to 7 days. This syndrome arises from a defect in the
mevalonate kinase gene, which also affects IL-b secre-
tion. Rash is common, and the lesions can be macules,
papules, urticarial lesions, or nodules. Amyloidosis has
not been reported. The differentiating features of the hy-
per IgD syndrome include lymphadenopathy, increased
serum IgD (>100 U/mL), and decreased mevalonate ki-
nase in the urine during attacks. Third, the Muckle-Wells
syndrome is autosomal-dominant and is distinguished by
amyloidosis, progressive sensorineural hearing loss, and
febrile urticaria. Fourth, the familial cold autoinflamma-
tory syndrome (FCU), like Muckle-Wells syndrome, is
autosomal-dominant [6, 39, 52]. It typically lasts only 1
or 2 days and is diagnosed by urticaria that occurs after
cold exposure. The mutations in FCU occur in the CIAS1
gene coding for cryopyrin (contains a pyrin domain in
the N-terminal). Amyloidosis is common. Fifth, the syn-
drome of chronic infantile neurologic cutaneous articu-
lar (CINCA) syndrome, or neonatal onset multisystem
inflammatory disease (NOMID) is of variable duration
and has an autosomal-dominant pattern of transmis-
sion [38, 39]. CINCA/NOMID arises from mutations in
the CIAS1 gene coding for cryopyrin. Amyloidosis has
been reported, and the associated rash is urticaria-like.
This syndrome is differentiated by neurologic manifesta-
tions ranging from mental retardation and chronic aseptic
meningitis to hearing loss. Arthropathy has a character-
istic appearance, with osseous overgrowth of the patella
and contraction of the knee. Finally, the last of these rare
syndromes is characterized by the clinical triad of pyo-
genic arthritis, pyoderma gangrenosum, and acne.
Prior to around 1973, therapy for FMF was lim-
ited to symptomatic treatment, but the introduction
of colchicine changed the fate of the disease. Effec-
tive colchicine therapy prevents secondary renal amy-
loidosis [5, 48]. Colchicine inhibits leukocyte chemotaxis
through a direct effect on cytoplasmic microtubules [4,
28]. Symptomatic pain relievers and nonsteroidal anti-
inflammatory drugs are given for the acute attacks. Pred-
nisone and immunosuppressive agents can be useful if the
patient develops vasculitis.
Unfortunately, all patients with renal impairment and
some with nephrotic syndrome will progress to end-stage
renal failure in spite of the institution of colchicine ther-
apy, as was the case in our patient. He progressed to end-
stage renal failure quite rapidly. His grave course was
complicated by uncontrolled inflammation.
Once renal failure occurs, renal replacement treat-
ment should be started, although in FMF patients, ther-
apy is associated with some particular complications [53].
Hemodialysis can pose problems because of the particu-
larly low intravascular volume in these patients. Throm-
bosis of the vascular access is more frequent in patients
with FMF. Our patient experienced problems with his ac-
cess as well. Continuous ambulatory peritoneal dialysis
also can be instituted, but it sometimes increases abdom-
inal febrile attacks [2].
Renal transplantation should be considered as an
effective treatment of end-stage renal disease for pa-
tients with amyloidosis secondary to FMF. After renal
transplantation, colchicine is mandatory [54, 55]. Insuf-
ficient doses cause a recurrence of renal amyloidosis in
the transplanted kidney. However, cyclosporine induces
colchicine toxicity and thus should be monitored ap-
propriately or an alternative immunosuppressive regime
should be used [54]. One should lower the dose of cy-
closporine A in these patients [2]. In the few series com-
paring 5-year patient and graft survival rates with those
in other nephropathies, the rates were some 5% to 20%
lower in amyloidosis patients [56, 57].
Permit me to make some concluding remarks. Physi-
cians practicing in the eastern Mediterranean area have
seen many patients with amyloidosis secondary to FMF.
With increasing education of general physicians, we’ve
seen a marked decrease in the number of patients devel-
oping amyloidosis. On the other hand, improved socioe-
conomic features might have contributed to this decline,
perhaps like the decline claimed in amyloidosis in Ar-
menian patients in the United States. If it is rarer in the
United States, why a difference exists in the predispo-
sition to amyloidosis in these patients is an intriguing
question. The predilection might be explained by the in-
creased stimuli by certain bacterial antigens to the innate
immune system that heightens the inflammatory milieu.
Further studies on the interactions of pyrin will shed light
on this subject.
QUESTIONS AND ANSWERS
Dr. John T. Harrington (Division of Nephrology, Tufts-
New England Medical Center, Boston, Massachusetts,
USA): What is known about the structure of pyrin, and
how does it preferentially increase Th1? Second, does
TNF-a have a direct effect in patients with FMF amyloi-
dosis?
Dr. Ozen: Pyrin is a protein that contains a “pyrin”
domain, a B-box type zinc finger, a coiled coil, and a
B30.2 domain [1, 8]. The “pyrin” domain is responsi-
ble for the protein:protein interaction. It interacts with
an “apoptosis-associated speck-like protein containing a
caspase recruitment domain (CARD)” that is abbrevi-
ated as ASC [8]. ASC is an adapter protein involved in
apoptosis and inflammation. This interaction likely me-
diates assembly of large signaling complexes and also
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activates caspase-1 [58]. Caspase-1 is then responsible for
the secretion of IL-1b and IL-18 [58]. ASC also activates
NF-jB, adding to the inflammatory signal. We still are not
sure how these events lead to a preferential T-helper 1 ac-
tivation, but we know that IL-18 is one of the activators
of the Th-1 pathway.
As to TNF-a, some authors have reported increased
levels in FMF [59]. However, the role of TNF-a in amyloi-
dosis cannot be commented on since the aforementioned
studies have enrolled patients without amyloidosis. One
study indirectly studied the association by analyzing the
TNF-a 308 G-A allele in patients with amyloidosis: this
polymorphism is associated with higher plasma levels of
TNF-a. However, the authors found no significant dif-
ference between the controls and FMF patients with and
without amyloidosis for this polymorphism [60]. We have
confirmed these data [43].
Dr. Marc de Broe (Professor, University of Antwerp,
Belgium): FMF is an inflammatory disease, involving neu-
trophils and macrophages. Acute ischemic/toxic injury is
an inflammatory disease, as in acute rejection. Is there in-
formation available concerning the incidence and clinical
expression of acute renal failure and acute rejection?
Dr. Ozen: In the reported series of transplanted FMF-
amyloidosis patients, the acute rejection episodes are not
increased as compared to the other transplanted patients
[56, 57, 61]. Although FMF is indeed a neutrophil disease,
a specific function is affected, and we can speculate that
this gene is not crucial in the immunologic events leading
to rejection.
Dr. Mustafa Arici (Associate Professor, Hacettepe
University, Ankara, Turkey): After 30 years, colchicine
remains the sole therapeutic agent. Angtiotensin-
converting enzyme (ACE) inhibitors and angiotensin II
(Ang II) receptor blockers are effective renoprotective
agents in proteinuric renal diseases. Is there any evidence
that these drugs are also effective in retarding progression
of amyloidosis in FMF patients with severe proteinuria?
Dr. Ozen: So far there is no evidence-based data on the
effect of ACE inhibitors or Ang II receptor blockers in the
prognosis of amyloidosis secondary to FMF. However,
we have recently started using these drugs in our patients
with proteinuria. We will have to wait to see the reports
on the use of these drugs.
Dr. Bulent Altun (Associate Professor, Hacettepe Uni-
versity): Do we have data about the anti-inflammatory
cytokine gene polymorphisms or cytokine levels such as
IL-10? Also, should we titrate the dose of colchicine in
accordance with genotype to prevent amyloidosis?
Dr. Ozen: Actually, in the study I presented from
our lab [18], intracellular staining for IL-4, an anti-
inflammatory cytokine, was measured by fluorescence-
activated cell sorter (FACS) analysis. Using peripheral
blood mononuclear cells from FMF patients, we found
that IL-4 was not expressed in these samples. In one study,
the serum levels of another anti-inflammatory cytokine,
IL-10, did not differ from those in controls, whereas the
inflammatory cytokines that were studied were increased
[59]. Most studies in FMF have measured inflammatory
cytokines only and have found them to be increased, as
one might expect.
We know that some mutations such as the E148Q are
associated with nonpenetrance and a milder phenotype
[15, 20, 62]. However, we do not have evidence-based
data that the colchicine dose can be titrated according to
the mutation. On the other hand, SAA monitoring might
be a good alternative for titrating doses of colchicine
[62–64].
Dr. Necla Buyan (Professor, Gazi University Faculty
of Medicine, Turkey): What is the sufficient dosage of
colchicine for certain pediatric ages? What can we do for
the patients with severe gastrointestinal side effects of
colchicine?
Dr. Ozen: The dosage of colchicine in pediatric prac-
tice is a matter of debate. One suggestion has been that
we use 0.03 mg/kg/day in children [64], while the adult
literature suggests that we administer the adult dose to
children [2]. However, I do not think a 10 kg child would
safely tolerate a 1.5 mg/day dose. In our practice, we give
the adult dose only after the child’s body surface area ex-
ceeds 1 square meter, which is roughly 29 kg. On the other
hand, data from the last FMF meeting suggest that the
SAA level is a critical factor in defining the risk of amy-
loidosis. We have shown that the SAA level was the best
index for inflammation and that increasing the colchicine
dose dramatically decreased SAA levels [64]. Thus we
have started to use SAA levels routinely in children to
titrate the colchicine dose. We tend to start at an arbi-
trary dose and titrate it according to the SAA, C-reactive
protein levels, symptoms and side effects of colchicine,
which mainly is diarrhea.
Severe gastrointestinal involvement of secondary amy-
loidosis is a major problem. It causes intractable diarrhea
and it is very hard to manage. There is some evidence for
the use of a lactose-free diet, based on the observation
that colchicine might induce lactose deficiency [2]. An-
tidiarrheal agents are of variable success.
Dr. Sevgi Mir (Professor, Ege University, Izmir,
Turkey): Does this patient have siblings? If so, what is
the treatment policy?
Dr. Ozen: This question reminds us of an important
issue. One of our responsibilities as pediatricians is to
inquire about the siblings when we diagnose a patient
with FMF. Our patient did have a younger sister, who de-
scribed typical attacks of FMF. She was put on colchicine
immediately. We did not perform a genetic analysis on
her, because she had the typical phenotype with ele-
vated acute-phase reactants and a brother who already
had been clinically and genetically confirmed to have the
disease.
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Dr. Ferah So¨nmez (Associate Professor, Adnan
Menderes University, Aydin, Turkey): If your patient had
a brother 8 years old without any clinical findings of
FMF and amyloidosis, and if he were homozygous for
the M694V mutation, would you begin colchicine ther-
apy immediately?
Dr. Ozen: There is some controversy about whether
asymptomatic individuals should be treated. Some of our
colleagues in the United States do not give colchicine to
asymptomatic individuals. I would have given colchicine
to the asymptomatic brother, because he would have had
risk factors for the development of amyloidosis: amyloi-
dosis in the family, male gender, and the M694V hmozy-
gosity, although the risk of this genotype has not been
consistent, as we already said. Another reason I would
have given him colchicine is that we live in an area where
13% of the patients with FMF also have amyloidosis. I
may be biased because of having seen quite a number
of children suffering from this complication. For aymp-
tomatic patients, I suggest thoroughly discussing with the
family the risk factors that I mentioned.
Dr. Jorge Cannata-Andia (Professor, University of
Oviedo, Oviedo, Spain): Could you please further com-
ment on the articular and skeletal involvement in FMF,
mainly as they compare with other inflammatory dis-
eases?
Dr. Ozen: The articular manifestation of FMF is typ-
ically a monoarthritis affecting the knees and ankles [2,
62]. It is nonerosive and remits spontaneously. The other
autoinflammatory diseases occasionally mimic these ar-
ticular attacks. However, they have their own distinguish-
ing features and do not respond to colchicine [50, 52, 62].
I must add that a “protracted arthritis” has been de-
scribed in FMF, even progressing to joint replacement
[2]. Since the disease is so frequent in this part of the
world and is associated with an increased inflammatory
milieu, it is tempting to speculate that these patients have
another chronic disease superimposed on FMF.
Dr. Ruhan Dus¸unsel (Professor, Erciyes University,
Kayseri, Turkey): What is your recommendation about
immunosuppression therapy (time, dosage, etc.) in pa-
tients with amyloidosis? Can their relatives be living
donors?
Dr. Ozen: It is widely recommended that one decrease
the dose of cyclosporine A in FMF patients [54, 55].
The administration of a full dose of colchicine and cy-
closporine A is associated with increased side effects of
both drugs, such as severe myoneuropathy [65].
Relatives can and have been used as donors [54–57,
61]. However, one has to make sure that they are free of
symptoms related to FMF. A genetic analysis would be
appropriate when possible.
Dr. John Dirks (Professor, Chair, ISN COMGAN,
Massey College, Toronto, Canada): Colchicine has been
a considerable advance in FMF but it has limita-
tions. What would be the alternatives? What do you
postulate as molecular sites for possible therapeutic
interventions?
Dr. Ozen: Actually, I believe colchicine is a very
safe drug at the doses we use. Concerns about fertility
are not supported in the recent literature [28, 66, 67].
The drug’s low cost is another advantage. Interferon al-
pha has been suggested as an alternative treatment in
colchicine-resistant patients [68], but one has to recog-
nize its side effects when deciding whether to use this
drug.
In the future, stem cell treatment might be an alter-
native if we become more competent in the field. This
procedure can provide healthy leukocytes without the
genetic defect. Milledge et al [69] have reported a patient
who was cured of FMF when he underwent bone mar-
row transplantation for his primary disease. However, it
is not ethical to perform a bone marrow transplant in a
patient who has FMF only; for the time being, colchicine
is a much safer and effective option.
Dr. Harrington: What do we know about the effect of
colchicine on neutrophils at the molecular level?
Dr. Ozen: Colchicine inhibits leukocyte chemotaxis
and is mainly concentrated in neutrophils. The affinity
of colchicine for neutrophils might be due to the absence
of the P-glycoprotein efflux pump on their membranes
[67] and might explain how the high concentration of
colchicine in these cells exerts its intracellular effect. Al-
though we don’t know its exact mode of action, colchicine
is thought to act on the microtubuli to effect chemo-
taxis. The drug also can reduce the expression of adhesion
molecules, thus interfering with leukocyte transfer to the
inflammatory site [4].
We do not know whether colchicine administration has
a direct inhibitory effect on the formation of amyloidosis
as well, other than through its anti-inflammatory effect.
However, in a mouse model, it suppressed amyloidogen-
esis at a late stage [70].
We also use colchicine in another neutrophil disease,
Behc¸et’s disease, where it is effective for at least some of
the clinical features of the disease.
Dr. Mehmet Sukru Sever (Professor, Istanbul Univer-
sity School of Medicine, Turkey): Have any studies de-
scribed the permeability and survival of the peritoneal
membrane in patients who receive continuous ambula-
tory peritoneal dialysis as renal replacement therapy?
Dr. Ozen: I’ve seen no published data on this subject.
Theoretically, I would expect peritoneal survival in FMF
to be shorter because of all the inflammatory cytokines in
the peritoneum at the time of the attacks. Some of these
cytokines have a potential for producing fibrosis.
Dr. Nilgun Cakar (Associate Professor, Social Secu-
rity Children’s Hospital, Ankara, Turkey): What are the
suggestions for medical care during pregnancy in patients
with FMF?
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Dr. Ozen: During pregnancy, FMF attacks can lead to
miscarriage and other complications. We currently sug-
gest that women continue to take colchicine during preg-
nancy [28, 62, 66]. We also recommend amniocentesis
during gestation to detect chromosomal abnormalities
[66]. In patients with renal amyloidosis, renal function
can deteriorate during pregnancy [66].
Dr. Cem Sungar (Professor, Bayindir Hospital, Ankara,
Turkey): What are the consequences of colchicine toxic-
ity?
Dr. Ozen: Colchicine toxicity is a very severe clinical
entity with a high mortality rate. It can cause bone mar-
row depression, acute renal failure, hepatic toxicity, and
disseminated intravascular coagulopathy [71]. Unfortu-
nately, the drug is not dialyzable. Thus precautions should
be taken to keep the drug away from young children.
Dr. Gultekin Suleymanlar (Professor, Akdeniz Univer-
sity, Antalya, Turkey): Colchicine can interact not just
with cyclosporine but with other drugs as well. We have
observed severe rhabdomyolysis along with acute renal
failure in a patient who was receiving colchicine plus cy-
closporine and a statin. We also have experience with
mycophenolate mofetil (MMF) and colchicine; the com-
bination was associated with an increased severity and
rate of the gastrointestinal side effects of MMF [72] in pa-
tients with renal amyloidosis secondary to FMF. Thus, the
dose of MMF should be reduced, or azathioprine should
be substituted for MMF.
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